Background
==========

Central immune effector functions, e.g., the development of long-term immunological memory, homing to target tissues and effective immune-surveillance are, in part, determined by metabolic programming, which plays a role not only in cellular physiology yet also in immunopathology ([@B204]; [@B70]). A better understanding of the dynamic role of metabolic programming may devise new ways of targeted therapeutic intervention(s). Preclinical and clinical studies in patients with non-communicable diseases link metabolic cellular impairment with immune dysfunction ([@B92]). A shift in metabolite requirement appears to govern the nature and dynamics of the immune response in the host -- largely involving glucose or lipids and fatty acids (FA) ([@B128]; [@B250]). For example, aberrant glucose metabolism and subsequent impaired immune function in patients with diabetes mellitus (DM) increases the risk for infections that require hospitalization ([@B201]). Dietary practices, i.e., Mediterranean eating habits versus a classical, high-fat Western diet underline how a 'healthy diet' is generally able to reduce inflammation and infections ([@B139]). High blood glucose levels are associated with a higher incidence of pulmonary tuberculosis (TB) -- predisposing patients with type 2 DM (T2DM) to a higher risk of TB-related mortality despite antimycobacterial therapy ([@B55]). The World Health Organisation (WHO) and global clinical TB working groups have identified DM to be a major comorbidity for TB susceptibility ([@B137]; [@B129]; [@B75]). We review here the role of immunometabolism in the tissue microenvironment, the axis of the intestinal microbiome and tissue-associated immune responses and discuss how targeted therapies may shift the balance of dysfunctional, damaging or non-productive immune responses to protective immune reactivity patterns that allow the containment of pathogens -- or elimination of transformed host cells.

The Diseased Tissue Microenvironment as a Critical Modulator of Immunometabolism
================================================================================

In T cells, glucose metabolism via the glycolytic pathway as opposed to fatty acid oxidation (FAO) differs between various T-cell maturation/differentiation subtypes, i.e., those expressing the 'effector,' 'memory,' and the 'exhausted' functional phenotypes. The transmembrane channel glucose transporter 1 (Glut1) is mandatory for cellular glucose uptake to fuel mitochondrial ATP generation, which plays a cardinal role in initiating IFN-γ gene transcription during an inflammatory response to fuel anti-tumor T-cell functions and cellular proliferation ([@B19]; [@B250]). Glut1 is induced by interleukin (IL) 7, a quintessential homeostatic cytokine necessary for the formation and maintenance of memory T-cell responses ([@B257]). Along with the engagement of signal transducer and activator of transcription 5 (STAT5), IL-7 promotes cellular glucose uptake and survival ([@B257]). The biological significance of IL-7 has been consolidated in translational and clinical studies to improve host immunity to infectious diseases by activation of CD4+ T-cell populations and re-programming of the antigen-specific T-cell repertoire in the context of TB, human immunodeficiency virus (HIV) infection and sepsis in preclinical ([@B133]; [@B238]; [@B185]; [@B114]) as well as clinical settings ([@B213]; [@B124]; [@B65]).

The presence of extracellular lactate has been shown to be associated with (human) T-cell proliferation *in vitro* and CD4+ T-cell activity ([@B80]). Importantly, CD4+ effector T cells also produce lactate which abrogates regulatory T-cell (Treg) responses and promotes Th17 development ([@B86]; [@B80]), which is reversible by blocking aerobic glycolysis ([@B86]; [@B51]). However, an earlier study showed that lactate produced by tumor cells can inhibit cytolytic activity of human CD8+ effector T cells *in vitro* ([@B61]). Memory CD8+ T cells rely more heavily on fatty acid oxidation (FAO) compared to effector T cells, where glucose breakdown leading to pyruvate production is crucial ([@B169]; [@B162]). Tregs also rely greatly on FA metabolism in an adenosine monophosphate-activated protein kinase (AMPK)-dependent manner, therefore raising the possibility of Treg survival in an environment enriched with high bioavailability of FA species ([@B154]).

*Mycobacterium tuberculosis* (*M.tb*)-infected macrophages experience a shift from oxidative phosphorylation (OXPHOS) to aerobic glycolysis *in vitro*, which leads to abrogated IL-1β production and increased IL-10 synthesis associated with intracellular mycobacterial growth ([@B77]). This also resonates with the observation that individuals with T2DM, having high blood glucose, exhibit impaired TB disease control ([@B247]; [@B58]; [@B55]). In mice infected with *M.tb*, Glut1 transcription is upregulated, in addition to the transporter associated with lactate secretion ([@B206]), which might have a negative effect on bystander effector CD8+ T cells ([@B204]). Of note, glucose transporters (including Glut1) as well as the ADP-dependent glucose kinase (ADPGK), which is associated with metabolic T-cell activation in active pulmonary TB, are also upregulated in lung granulomas from patients with active TB ([@B215]; [@B206]). The lung pathogens *Staphylococcus aureus* and *Bordetella pertussis* also perpetrate dysregulated glucose metabolism in the host, with the latter directly causing insulin resistance by negatively regulating blood glucose homeostasis ([@B243]; [@B14]; [@B67]). Rats fed with a high-fat diet (in relation to obesity) were shown to present with an accumulation of inflammatory macrophages characterized by Glut1 upregulation as well as IL-6 and TNF-α expression in adipose tissue and the liver ([@B66]). Glut1 overexpression enhanced glucose uptake and glycolysis in these macrophages, further to upregulation of other pro-inflammatory mediators such as CCL5 (also called RANTES), necessary for CD8+ T-cell activity against viral infections ([@B30]) and granulocyte-colony-stimulation factor (G-CSF), which promotes neutrophil growth, downregulation of IL-17 production ([@B140]) and potentially expands central memory G-CSF receptor-expressing CD4+ IL-4+ Th2 cells in human blood ([@B134]). Immunological mediators, measured at various time points in individuals with metabolic disorders, i.e., obesity and diabetes, may hold great clinical value in terms of preventing full-fledged pulmonary infections particularly TB with respect to devising host-directed immunotherapeutic interventions ([@B181],[@B182]).

Disbalance in glucose metabolism triggered by influenza virus has been reported in pediatric patients, which was found to be reversible by pharmacological inhibition of the phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway ([@B212]). Pertaining to HIV infection of macrophages, the glycolysis-associated enzyme hexokinase 1 (HK-1) has been shown to bind to mitochondria to increase its membrane potential and support the survival and maintenance of infected cells. The common antifungal agent clotrimazole can inhibit HK-1 activity in macrophages, thereby unleashing caspase 3/7-mediated apoptosis ([@B199]). Inhibition of HK-2 can has also been shown to promote skewing of human CD4+ T cells to acquire a regulatory phenotype ([@B51]). Enhanced mitochondrial membrane potential to support pathogen replication has also been attributed to the infection of epithelial cells with *Chlamydia pneumoniae*, an important intracellular bacterial parasite, under normoxic conditions further to increased expression of NADPH in host cells ([@B101]). Glucose uptake is also necessary for B-cell proliferation and antibody production, which has been shown to depend on PI3K activity in association with an increase in lactate production ([@B46]; [@B21]). This balance is disrupted in patients with T2DM, manifesting in exaggerated and deleterious pro-inflammatory immune responses ([@B42]) which possibly makes patients with T2DM more susceptibility to TB and other pulmonary infections compared to non-diabetic individuals ([@B23]; [@B184]). Collectively, these 'shunting' mechanisms of host metabolism support pathogen survival either directly or by manipulating the immune system and may, therefore, represent an 'immune escape strategy' used by pathogens.

New research has shed light on the role of glycolysis in subduing T-cell infiltration into tumors as well as the ability of T cells to kill target cells, concomitant with downregulation of interferon regulator factor 1 (IRF1), an essential interferon gamma (IFN-γ) response element ([@B22]). Since host molecules linked to glucose transport and metabolism are activated in human TB granulomas, it appears that the glycolytic pathway could potentially affect effective T-cell responses in pulmonary TB. Glucose metabolism in CD4+ T cells during chronic HIV infection also promotes activation, marked by Glut1 and upregulation of the major histocompatibility class II (MHC-II) molecule human leukocyte antigen-DR (HLA-DR) ([@B166]), a marker of T-cell activation. At the same time, this T-cell subset is also depleted regardless of antiretroviral therapy (ART). A similar pattern of increased glucose metabolism and Glut1 expression profile has been observed in monocytes derived from patients with HIV, irrespective of ART status ([@B165]).

[L]{.smallcaps}-arginine is also necessary for T-cell survival; elevated levels are metabolized by arginase 2 (ARG2) in mitochondria to induce OXPHOS, switching from glycolysis, for production of ATP via the electron transport chain ([@B74]). Increased [L]{.smallcaps}-arginine uptake by T cells promotes the expansion of central memory T-cell subsets (CCR7+) in addition to acquisition of effector functions, i.e., IFN-γ production even in the absence of T-cell homeostatic cytokines such as IL-2 or IL-15 ([@B74]). *M.tb*-infected macrophages present at the hypoxic center in TB lung granulomas in a murine model of pulmonary TB have been previously shown to utilize ARG1, *in lieu* of NOS2, to catabolize [L]{.smallcaps}-arginine ([@B49]). This reduces T-cell proliferation and the resulting immunopathology while abrogation of ARG1 enzymatic activity exacerbates lung pathology ([@B49]).

Excessive glucose uptake by activated T cells as well as macrophages during inflammation has been observed in conjunction with hypoxia. Response to hypoxia by 'foamy' macrophages in atherosclerotic plaques as well as migratory CD8+ T cells during inflammation, marked by hypoxia-inducible factor 1 alpha (HIF-1a) expression, has been observed to elevate glucose uptake ([@B62]; [@B60]). 'Foamy' macrophages are cytoplasmic lipid-enriched cells associated with atherosclerotic plaques which, due to dysregulation of cholesterol metabolism, accumulate intracellular cholesteryl ester deposits ([@B146]). Hypoxic TB lesions/granulomas in the lung have also been shown to display an accumulation of 'foamy' macrophages which can be induced by *M.tb*-derived lipids, i.e., mycolic acids species ([@B173]) as well as host-derived triglyceride esters in necrotic lesions ([@B81]; [@B98]) and are capable of local modulation of T-cell responses ([@B176]). Although yet to be formally tested, hypoxia-induced 'foamy' macrophage accumulation may also pose the likelihood of affecting positron emission tomography-computed tomography (PET-CT) readouts in pulmonary TB imaging due to the increased glucose uptake by and glycolytic activity of macrophages in granulomas ([@B68]; [@B210]; [@B72]). In addition, recent evidence suggests that *M.tb*-infected macrophages accumulate intracellular lipid droplets following IFN-γ-dependent immune activation rather by direct, pathogen-derived mechanisms ([@B110]). This feature was found to benefit the host in a murine model of pulmonary TB, although the metabolic profile of immune cells is likely to shift with a high amount of lipid intake -- potentially promoting FAO and longevity of the cells in tissue ([@B186]).

The afore-mentioned HIF-1α has also been shown to be induced in HIV-infected macrophages, involved in the upregulation of HK-1 for supporting viral replication and biogenesis ([@B10]), warranting further elucidation of the HIF-1α axis in TB/HIV co-infection in relation to immunometabolism. *C. pneumoniae*-infected epithelial cells have also been shown to upregulate enzymes involved in hypoxia-induced glycolysis, i.e., phosphofructokinase, lactate dehydrogenase and glycerol-3-phosphate dehydrogenase which promote pathogen survival ([@B220]). Furthermore, *C. pneumoniae* infection itself directly stabilizes HIF-1α expression to enhance glycolysis ([@B192]), which is also likely to dampen HLA class I antigen processing, presentation and immune surveillance as observed in cancer ([@B200]). Epstein-Barr virus (EBV) and CMV are known downmodulators of the HLA class I pathway ([@B123]; [@B12]), while *M.tb* early-secreted antigenic target of 6 kDA (ESAT-6), an immunodominant antigen, has been shown to interfere with beta-2-microglobulin (β2M) insertion into the HLA class I complex within the endoplasmic reticulum ([@B214]). Thus, testing whether alteration of glucose uptake during infection with intracellular pathogens would improve HLA class I antigen presentation using clinically relevant models would be very useful to devise immuno-stimulatory interventional strategies.

Fatty Acids and Immunometabolism
--------------------------------

The availability of free fatty acids (FFA) and the intracellular biosynthesis of lipid droplets in T cells following glucose metabolism has a drastic impact on T-cell functionality and polarization ([@B38]). As mentioned previously, FAO is a quintessential metabolic program in memory CD8+ T cells for their development, sustenance and immuno-protective activity in the host ([@B169]; [@B235]; [@B162]). Saturated FFA, i.e., palmitic acid, lauric acid, myristic acid as opposed to unsaturated FA, such as oleic acid and linoleic acid, appear to be generally less toxic and promote *less* inflammatory responses by human T cells ([@B127]; [@B32], [@B31]). Conversely, saturated FA have been shown to impair HLA class I antigen processing and presentation, resulting in reduced recognition and killing of target cells by FA-exposed human CD8+ T cells ([@B202]). Similarly, palmitic acid-treated APCs were also unable to activate naïve CD8+ T cells, which resonates with the earlier finding that saturated FA do not trigger strong inflammatory responses ([@B202]). In addition to CD8+ T-cell activation, a reduced exogenous supply of FA has also been attributed to compromised HLA-DR (major HLA class II molecule in humans) expression profile, in part owing to impaired lysosomal activity -- which was rescuable with coenzyme-A (CoA)-coupled unsaturated FA, i.e., oleic and linoleic acids ([@B198]). Human adipose tissue-derived stem cells (ASCs) from obese individuals have also been shown to exhibit increased HLA-DR expression albeit with lesser cytoplasmic lipid-droplet accumulation ([@B164]), possibly due to increased cellular oxygen consumption leading to depletion of fat deposits in ASCs ([@B171]). Another preclinical study in mice provided evidence that a high fat diet-induced upregulation of MHC-II, leading to generally increased inflammatory responses, lowered anti-inflammatory responses and M1-polarized pro-inflammatory macrophages ([@B43]). While in the afore-mentioned study this MHC-II-driven immune activation was identified as an important perpetrator of obesity, this may, on the contrary, be beneficial in the context of pulmonary infections at the initiation of host immune responses targeting pathogens ([@B269]). Nutrition may, therefore, indirectly affect susceptibility to pulmonary infections -- as with TB ([@B64]) and recurrent respiratory infections among children ([@B264]). In addition to T cells, the requirement of FA by antigen-presenting cells (APCs), i.e., macrophages, dendritic cells and B cells has also been reported to be crucial for activation, phagosome--lysosome fusion, antigen processing and presentation via HLA-DR expression -- as well as anchoring proteins into lipid rafts on the cell surface ([@B18]; [@B198]).

The discussion presented above warrant deeper insights into the various mechanisms by which FA-mediated metabolic programming in immune cells, adaptive and innate alike, shape the immune repertoire in humans -- particularly in pulmonary infections and associated diseases ([@B112]).

Pulmonary Surfactants in the Context of Lung Immunometabolism
=============================================================

An important lipoprotein class unique to the lungs are pulmonary surfactants, which are produced by type II pneumocytes and crucial for reducing surface tension, gas exchange functions, tissue integrity and host defense ([@B259]). Two members of lung surfactants, namely SPA-A and SPD-D, also possess immune-related properties. SP-D is mainly associated with opsonization of Gram-negative bacteria by binding to the LPS moieties on the bacterial surface for subsequent engulfment by innate immune cells -- which leads to activation of APCs and T-cell recruitment ([@B259]). SP-A, on the contrary, while capable of inducing IL-8 production by neutrophils and macrophage activation, can inhibit T-cell proliferation and the maturation of dendritic cells ([@B259]). While important in clearing Gram-negative bacterial infections, e.g., *Pseudomonas* sp. and streptococcal infections, individuals with chronic autoimmune manifestations, i.e., ARDS, sarcoidosis and pulmonary fibrosis also exhibit impaired surfactant functions ([@B89]). The homeostasis of cholesterol, the major neutral lipid of pulmonary surfactants, requires ATP-binding cassette transporter G1 (ABCG1) and ATP-binding cassette transporter A1 (ABCA1) activity without which cholesterol build-up in the alveolar air space can occur in addition to the accumulation of 'foamy macrophages' ([@B8]; [@B258]; [@B47]). In keeping with this, ABCG1-deficient macrophages can also be found in patients with pulmonary alveolar proteinosis (PAP) -- a rare disease characterized by the build-up of surfactant in the alveolar space ([@B17]) -- in conjunction with autoantibodies against GM-CSF blocking its signaling cascade ([@B226]).

Impaired lipid efflux functions have been demonstrated in immune cells from patients with chronic lung diseases. Some examples are ABCA1 and ABCG1, downregulated in lung-resident immune cells from patients with sarcoidosis ([@B9]); compromised activity of the transcription factor liver X receptor (LXR); reduced plasma levels of alveoli-derived cholestenoic acid in patients with TB, emphysema as well as sarcoidosis ([@B5]) and the absence of ABCG1 expression in PAP ([@B37]). Accumulation of foamy cells in smokers -- a strong comorbidity factor in lung infections ([@B255]) -- reflects impaired lipid cellular metabolism, as reduced levels of apolipoprotein A1 (ApoA1) are found in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis (IPF) ([@B108]). These indicators may provide a clinically relevant matrix concerning an individual's susceptibility to contract pulmonary infection(s) ([@B76]) while aiding the development of targeted treatment strategies.

While patients with PAP harboring ATP-binding cassette deficiency are prone to opportunistic lung infections ([@B78]; [@B17]), TB or mycobacterial infections in general, it has also been implicated in the pathogenesis of sarcoidosis ([@B236]; [@B59]), suggesting an overall impaired host defense involving pulmonary surfactant disbalance. Interestingly, ABCA1 loss in murine alveolar macrophages enhanced pro-inflammatory immune responses in the lung and clearance of bacterial infection ([@B47]), which requires well-designed studies in humans. Taken together, surfactant/lipid homeostasis in the lung, pertaining to cholesterol metabolism, suggests a critical role in balancing pulmonary inflammation. Herein, the ABC transporters associated with lipid homeostasis in the lung play a crucial role in mediating local immune responses and pathogen control.

Metabolic Reprogramming of Natural Killer Cells in Infected Tissue Compartments
===============================================================================

Akin to metabolic changes experienced by T and B cells during pulmonary infections, natural killer (NK) cells also appear to undergo similar tissue-associated 'metabolic stress' which affects their capacity to clear infectious pathogens ([@B70]). While NK cells play a role in halting development of active TB in individuals with LTBI ([@B69]; [@B191]), circulating IL-6Rα+ NK cells in T2DM have been shown to perpetrate deleterious inflammation ([@B225]), with the likelihood of affecting NK-cell activity in the lung. The functionality of NK cells in obese individuals also appears to be compromised and is further accentuated by exposure to cigarette smoke ([@B161]; [@B117]) -- which subdues host defense mechanisms in general, particularly in the lungs ([@B7]; [@B130]). In humans, CD56^bright^ NK cells exhibit reduced cytotoxic functions (granzyme, perforin production) albeit superior IFN-γ production compared to CD56^dim^ NK cells. Furthermore, CD56^bright^ NK cells constitute the most frequent tissue-resident population, while CD56^dim^ NK cells comprise approximately 90% of circulating NK cells ([@B71]). Adaptive, memory-like NK cells have also been described to share similarities with memory CD8+ T cells in terms of DNA promoter region hypermethylation patterns ([@B195]). Memory-like NK cells display reduced expression of the Fc gamma receptor III (FcγRIII and CD16) -- necessary for antibody-mediated cellular cytotoxicity (ADCC) ([@B244])-- although in the presence of IgG antibodies, these NK cells regain cytotoxic function and specifically lyse human cytomegalovirus (HCMV)-infected cells ([@B120]).

Despite limited knowledge about metabolic programming in human NK cells, some *in vitro* studies have shown that upregulation of mTOR complex 1 (mTORC1) in CD56^bright^ NK cells, more reflective of a less mature subpopulation, promotes their uptake of glucose and responsiveness to IL-15 signaling ([@B138]; [@B104]; [@B136]). CD56^bright^ NK-cell proliferation also promotes upregulation of Glut1 and renders these cells metabolically more active than their CD56^dim^ counterparts ([@B104]). In line with this, glycolysis is necessary for CD56^bright^ NK cells to produce IFN-γ, which is among their primary effector functions in addition to cytotoxicity ([@B29]). Therefore, NK cells in tissue may necessitate increased glycolytic activity while maintenance of memory-like populations marked by CD57 and CD16 expression as well as enhanced cytotoxic capacity -- akin to memory CD8+ T cells -- might require FAO ([@B103]; [@B170]), although this demands formal testing using *ex vivo* material from healthy subjects as well as in patients with infections (e.g., TB), or malignancies.

MicroRNAs and Metabolic Programming During Lung Infection Pathology
===================================================================

Inflammation drives the biosynthesis of certain microRNAs (miR) -- short molecular structures which post-transcriptionally regulate gene expression -- that can directly influence the metabolic profile of immune cells during infectious disease pathogenesis ([@B95]; [@B96]; [@B193]; [@B266]) and cancer ([@B227]). The Let-7 family of microRNAs reduce the ability of B cells to take up glucose and glutamine from their immediate microenvironment due to downregulation of transport channels, which results in loss of IgM production ([@B100]). While Let-7 upregulation has been observed in hepatocellular carcinoma in association with disease severity ([@B207]), a cancer attributed to viral infection and inflammation, Let-7 upregulation has been associated with protective anti-viral (HIV) cellular CD4+ T-cell responses ([@B219]). Furthermore, the decreased expression of Let-7 in CD8+ T cells -- downstream of T-cell receptor (TCR) activation -- allows for the acquisition of effector functions ([@B252]), underlining that metabolic shifts affect different immune-cell subsets in several ways.

Not only immune cells yet also stromal cells or transformed cells are affected by such metabolic shifts. For instance, miR-155 has been implicated in supporting the growth of breast cancer cells by enhancing glucose metabolism ([@B107]); the same microRNA also promotes the intracellular survival of *M.tb* by inhibiting autophagy in infected myeloid cells ([@B53]). A previous study showed that miR-155 is upregulated in peripheral blood mononuclear cells (PBMCs) from patients with active pulmonary TB and a mechanistic *in vitro* approach was used to demonstrate that the Foxhead-box protein O3 (FOXO3) transcription factor is targeted by miR-155 to abrogate apoptosis of *M.tb*-infected cells under normoxic conditions ([@B94]). Interestingly, FOXO3 is known to be involved in regulating mitochondrial respiration during hypoxia and inhibiting reactive oxygen species (ROS) generation ([@B57]), which is also characterized by aberrant vascularization in inflamed tissue ([@B222]). Considering that tissue hypoxia is associated with several infectious diseases of the lung, i.e., TB, leishmaniasis ([@B194]) and legionellosis ([@B203]) as well as solid tumors, FOXO3-mediated activity may increase local apoptosis of transformed cells, which has been shown in the context of cancer ([@B48]).

The Host Microbiome and Productive Immune Responses to Pulmonary Infections
===========================================================================

'Metabolic programming' in the host -- to a great extent modulated by the gut microbiota -- takes place in the small intestine and colon - and affects the quality and quantity of immune responses occurring in other parts of the body ([@B3]; [@B56]). While translocation of gut pathobionts can induce unfavorable immune responses elsewhere in the body ([@B135]), inflammatory response originating in the gut can equally influence how the host responds to an invading pulmonary pathogen ([@B145]). *Candida albicans*, a yeast species which is a commonly found member of the human gut microbiome, can activate CD4+ T cells which produce IL-17 and possibly traffic to the lung, where they can specifically cross-react with antigens from *Aspergillus fumigatus* ([@B6]), the aetiological agent of invasive pulmonary aspergillosis (IPA). These IL-17 responses were very prominent in patients with airways diseases such as chronic obstructive pulmonary disease, asthma (although this is often associated with a Th2 responses, i.e., IL-4, IL-5 production) and cystic fibrosis ([@B6]). Importantly, patients with Crohn's disease, a debilitating form of inflammatory bowel disease, had high frequencies of IL-17-producing, *C. albicans*-specific CD4+ T cells ([@B6]). While dysregulation of the microbiota may lead to activation of IL-17-producing cells which can translocate to the lung to cause pathology locally, the same type of IL-17+ T cells may also be protective in early stages of infection, as shown in preclinical mouse models of pulmonary infections (reviewed by Das and Khader in [@B36]). This hypothesis, however, requires formal testing in clinically suitable models which closely resemble the disease immunopathology in humans.

However, not only 'distant' effects of tissue/organ-associated microbiomes, i.e., the gut-lung axis, affect lung-resident immune cells, yet the local pulmonary microbiome itself maintains tissue integrity and regulates local immune responses ([@B158]). In human avian influenza A H7N9 infection, several FA species were shown to be reduced in the peripheral blood associated with impaired patient survival ([@B218]). This observation was accompanied by histological evidence of severe lung inflammation, supported by molecular analyses showing downregulation of genes associated with lung epithelial barrier integrity ([@B218]) -- in which the lung microbiome plays a role. Resonating with this observation is the finding that tissue-resident CD8+ T cells require an external supply of FA for their survival, via the activity of fatty-acid-binding proteins 4 and 5 (FABP4 and FABP5) ([@B167]). This may -- at least in part -- explain as to why high numbers of activated CD8+ T cells, including those that can home to tissue compartments, are elevated in patients with HIV receiving ART ([@B150]), leading to increased circulating cholesterol and triglycerides ([@B155]).

Bacteria also produce their own metabolites which can alter immune functions ([@B56]). FA production by commensal intestinal bacteria -- that constitute the host gut microbiome -- may complement the FA source needed for memory CD8+ T-cell homeostasis ([@B131]). Antibiotic-associated clearance of commensal bacterial species can potentially have a drastic effect on the survival of memory CD8+ T cells in the host ([@B105]), as shown in mice and warranting confirmation in humans. Microbial metabolites, i.e., short-chain fatty acids (SCFA; acetate, propionate, butyrate) can induce IL-18 production by epithelial cells while also tuning the differentiation of B cells in to plasma cells, antibody production and IgA class switching ([@B208]). Butyrate promotes IL-10 production, tight junction formation between epithelia and downregulation of pro-inflammatory responses in human intestinal cells ([@B265]). In a murine model of azoxymethane/dextran sodium sulfate (AOM/DSS)-induced colitis, mice treated with a mix of SCFAs (acetate, butyrate, and propionate) were shown to be protected against colon inflammation concomitant with reduced expression of IL-6, TNF-α, and IL-17A ([@B228]), suggesting regulation of both pro- and anti-inflammatory immune responses by SCFAs. This is in line with clinical observations of patients with inflammatory bowel disease (IBD) such as Crohn's disease or ulcerative colitis who present with gut microbiota dysbiosis marked by reduced numbers of SCFA-producing bacteria ([@B79]).

Another study in patients with HIV and bacterial pneumonia showed that the indigenous lung microbiome, containing a combination of bacterial communities (annotated by the authors as microbial communities states or MCS) represented by *Pseudomonadaceae* with a mixture of *Sphingomonadaceae* and *Prevotellaceae* (MCS1), was associated with a survival benefit as compared to individual grouped into other MCS characterized by an abundance of *Streptococcaceae* (MCS2A) or *Prevotellaceae* (MCS2B) ([@B205]). Interestingly, patients harboring the MCS1 lung microbiome profile also showed an increase in serum lipid metabolites further to upregulation of T-cell immunoglobulin and mucin domain 3 (TIM-3) in the lungs, based on chromatographic and mRNA analysis, respectively ([@B205]). Using fecal samples provided by individuals from Bangladesh and Tanzania, an intriguing study by [@B45] recently described the discovery and characterization of large bacteriophages containing more than 540 kilobases of genomic material (termed 'Lak megaphages') which, based on CRISPR sequences, specifically target *Prevotella* species in the human gut. The authors also found an abundance of *Prevotella* and Lak megaphages in human fecal samples to be inversely correlated. Thus, Lak megaphages may be an important indicator of gut microbiome health, given the benefit provided by *Prevotella* species in health and disease, which may be addressed in future clinical studies using appropriate cohorts.

Several studies in patients with TB have linked the gut microbiome with TB disease activity (reviewed in [@B91]). Individuals with LTBI exhibited a higher abundance of *Bifidobacterium* spp. in the gut compared to patients with active TB who underwent standard antimycobacterial therapy; higher abundance of *Bacteroides* spp. was found in the gut of patients who were cured of TB following therapy ([@B256]). In this regard, *Bifidobacterium* spp. have been associated with superior immune responses to respiratory infections, while *Bacteroides* spp. have been shown to rather augment antigen-specific, cancer-directed T-cell responses in the host ([@B63]; [@B174]). However, the presence of fat tissue affects the host immune response at different levels: white/beige adipose tissue deposits have been shown to accommodate memory T cells which can provide long-term protection against infections ([@B87]). Conversely, white adipose tissue is also associated with obesity and increased susceptibility to infectious diseases ([@B88]), while harboring viral and bacterial pathogens such a HIV and *M.tb* ([@B34]; [@B11]).

Microbial Metabolites and Immunomodulation in the Host
------------------------------------------------------

Further to the roles of microbial metabolites previously mentioned, SCFAs are able to prime the immune system by increasing the release of IL-18, prompt IgA production by plasma cells and activation of cathelicidin LL-37 (antimicrobial peptide) secretion along with retinoic acid production by APCs to potentiate first-line innate immune responses ([@B208]). However, butyrate can also induce Treg development and expansion in a sodium ion-dependent manner, which requires intracellular activation of indolamine-1,2-dioxygenase (IDO) ([@B85]), an enzyme necessary for tryptophan metabolism ([@B224]). Thus, there is a chance that butyrate in combination with IFN-γ -- which is the major inducer of IDO expression ([@B224]) -- can promote immune-tolerance in diseased tissue to avoid overt inflammation and also help to fine-tune antigen-specific T-cell responses ([@B116]). Nevertheless, and dependent on the stage and the nature of infection, Treg engagement may also dampen the formation of productive, pathogen-directed immune responses ([@B73]; [@B126]). Previous work has shown that depletion of intracellular tryptophan in relation to increasing IDO activation leads to impaired survival of *Chlamydia trachomatis*, which can also be potentiated by IL-1β in combination with low-dose IFN-γ ([@B20]). Tryptophan is sourced by dietary protein intake by mammals, which in the gut is catabolized by certain species of commensals, i.e., *Bacteroides* sp., *Clostridium* sp., lactobacilli ([@B188]). Metabolites resulting from tryptophan degradation can promote protection against fungal (and potential intracellular bacterial) pathogens in an IL-22- and aryl hydrocarbon receptor (AhR)-dependent mechanism ([@B263]). The AhR is generally a toxin-reactive (dioxin) host transcription factor which also has a role in sensing bacterial derivatives to engage immune responses in the lung ([@B149]). In mice, AhR has been shown to be indispensable for the development of IL-22+ NKp46+ innate lymphoid cells (ILCs) in the gut ([@B121]) and the importance of IL-22 in protection against intestinal infections ([@B83]) as well as lung tissue repair following severe influenza infection ([@B175]). [@B125] described a specialized population of gut-associated AhR-expressing intraepithelial lymphocytes (IELs) which responds to the synthetic tryptophan-derived phytochemical I3C, provides immune surveillance at the epithelial barrier and is able to control bacterial outgrowth following their translocation into the gut lumen. Branched SCFAs, i.e., isovalerate, isobutyrate, and valerate can have an inhibitory effect on histone deacetylases (HDACs), which may in turn downregulate the pro-inflammatory polarization of macrophages in the gut ([@B25]; [@B106]) -- based on studies in mice. These findings, therefore, implicate amino acid metabolism, SCFAs and cytokine signaling axes in maintaining host-protective immune mechanisms in tissue during infection and require confirmation in humans.

Long-chain fatty acids (LCFAs) such as arachidonic acid and linoleic acid, both of which are produced by host cells as well as gut bacteria, are known to modulate innate immune responses, i.e., downregulation of IL-6, IL-8, and IL-1β production, increased phagocytic potential of macrophages, increased IL-10 production by epithelial cells and activation of the eicosanoid pathway to produce prostaglandins ([@B208]). Arachidonic acid had already been shown (more than 20 years ago) to induce IgE and IL-4 production (strong Th2-skewed immunomodulation) in individuals with atopic dermatitis ([@B177]). [@B54] very recently showed that prostaglandin E2 (PGE2) production by the opportunistic fungal pathogen *Cryptococcus neoformans* activates peroxisome proliferator-activated receptor gamma (PPAR-γ) in host macrophages to support intracellular survival and proliferation. Pulmonary *C. neoformans* infections are rare, but can be burdensome and -- although treatment with fluconazole is highly effective ([@B102]) -- the effect of fluconazole on dysbiosis and immunometabolism is clinically relevant as seen in murine preclinical models ([@B254]) and warrants evaluation in humans.

The exposure of host cells to a broad array of metabolites produced by commensal and invading microbes, as well as the derivates thereof, requires further dissection in humans with different diseases. Future clinical studies may examine, based on previous observations in patients with metabolic disorders (IBD, diabetes, and chronic infections), where biomarkers were available, that metabolite imbalance and subsequent microbiota 'disruption' may lead to immune dysfunction ([@B106]). Similarly, novel biomarkers in pediatric patients are required to better understand the effect of dysbiosis in early childhood -- perpetrated by fatty liver disease, congenital diabetes and drug prescriptions -- and whether their value as clinical correlates of susceptibility to infection as well as autoimmune disease ([@B153]) is relevant or not. Target organs of immune-metabolites may also be distant anatomical sites: The role of the gut-lung axis in accentuating *trans*-anatomical immune responses is being increasingly appreciated ([@B145]; [@B6]), providing strong precedence to account for systemic and gastrointestinal health in patients with lung infections with a focus on circulating and locally available metabolites.

Microbiota and Immune-Modulation by Pre- and Perinatal Nutrition
----------------------------------------------------------------

Metabolic imprinting on immune cells may in fact occur early in life: while a common ante-natal nutritional source in developed nations (at least 80% of mother-child pairs), only a meager 37% of infants under 6 months of age in the developing world (low- to middle-income countries) are breastfed ([@B241]). Children who do not receive breastmilk in the first few months after birth have been found to be more prone to developing infections and reduced intellectual capabilities ([@B241]). Furthermore, mothers who do not breastfeed suffer a higher risk of contracting breast or ovarian cancer in their lifetime compared to women who breastfed their babies ([@B241]). More recently, [@B147] provided empirical evidence based on a large cohort study of 392 mother-infant dyads (pairs) comprising various ethnicities and found that direct breastfeeding was strongly associated with a higher prevalence of beneficial bacteria, i.e., *Bifidobacterium* supplied to infants as opposed to pumped breastmilk, which had a higher content of potentially pathogenic bacteria such as *Pseudomonas* spp. This would subsequently influence the infant's metabolic and immune profiles as well as their gut microbiota composition and how they would respond to infections ([@B119]). Breastfeeding has been previously shown to be closely associated with increased protection against bronchiolitis (usually due to a viral infection of the lower respiratory tract) in children under 2 years of age ([@B246]). Breastmilk composition could, therefore, be a crucial component of future clinical studies investigating immune dynamics as well as treatment outcome following diagnosis of respiratory infections in neo-nates.

All in all, antibiotics directly affect the composition of the microbiota in association with host factors, i.e., the HLA haplotype, lifestyle and environmental factors, i.e., high-fat diets, or uncontrolled glucose intake. These factors may be considered for a more holistic approach in the clinical management of patients with pulmonary infectious diseases. Furthermore, this may not only be conscious decisions of the individual yet also reflect social pressure and socio-economic differences including factors before birth including maternal nutrition, as discussed above.

Therapeutic Targeting of Host Immunometabolism
==============================================

Evidence stemming from cancer precision medicine offers a wealth of information to target host immunometabolism for therapeutic purposes, where the tumor microenvironment (TME) in solid tumors is an emerging drug target to induce disease-modifying effects ([@B118]; [@B245]). Much can be learned from the pathophysiological and immunological similarities between the TME and TB lesions in the lung ([@B240]; [@B13]; [@B33]), non-tuberculous bacterial pneumonia ([@B261]) and pulmonary fungal infections ([@B82]) to be applied for interventional purposes in infectious disease. For instance, the anti-diabetic drug metformin which modulates FAO in memory CD8+ T cells was shown to contribute to improved immune control and better outcomes in a preclinical (murine) TB model ([@B211]). In keeping with this observation in mice, a later clinical study demonstrated correlation with desirable clinical outcomes in patients with cancer and T2DM under metformin treatment ([@B267]). More recently, two retrospective clinical studies showed that metformin use in patients with T2DM, who also contracted pulmonary TB, was associated with improved prognosis after standard anti-TB treatment ([@B141]; [@B41]) while a third study revealed that patients with T2DM who received metformin therapy exhibited a lower chance of contracting active TB during anti-diabetic treatment follow-up ([@B122]). Likewise, zileuton, an anti-asthmatic drug \[thus representing yet another indication with immunometabolic dysregulation particularly in obese individuals ([@B172])\] which blocks the synthesis of 5-lipoxygenase and thus, leukotriene release, regulates IFN-αβ and IL-1β-associated adverse immunopathology in (murine) TB ([@B142]). Targeting epithelial-cell sphingolipid metabolism using miglustat (marketed as Zavesca^®^, a synthetic analog of [D]{.smallcaps}-glucose) resulted in reduced airway inflammation, neutrophilia and *Pseudomonas aeruginosa* burden in a murine infection model ([@B40]), further strengthening the case for drug-repurposing or multi-purposing.

Immunotherapy-Based Interventions
---------------------------------

Reversing glucose uptake by highly activated effector CD4+ T cells might be a viable option for therapeutic intervention to reduce overt inflammation ([@B132]) and possibly promote CD8+ T-cell activity ([@B216]). However, it may not necessarily affect antigen-specific tissue-resident T-cell subsets, which appear to rely more on lipid metabolism ([@B167]). Genetic manipulation of T cells, prior to adoptive therapy, may be used to change their metabolic profile and/or susceptibility to certain metabolites by introducing mRNA transcripts of proteins using a newly described microfluidic system, which also measures cell viability and motility in real-time ([@B99]). Analysis of programmed cell-death 1 (PD-1)- and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)-mediated immune-suppression showed that while the former shifts the cellular metabolic profile from glucose (glycolysis) to lipid-dependence (FAO), CTLA-4 engagement with CD80/86 leads to inhibition of glycolysis without augmenting the requirement for FAO ([@B168]). Immune checkpoint blockade (ICB) has been particularly successful in patients with metastatic melanoma and lung cancer ([@B187]). PD-1-expressing T cells may, in fact, display a metabolic profile resembling that of memory CD8+ T cells that rely on FAO for survival ([@B168]). Given that PD-1-mediated therapeutic intervention warrants clinical exploration in infectious diseases ([@B183]), it is worthwhile bearing in mind that the metabolic reprogramming of pathogen-specific T cells in lung infections is also possible with ICB.

Corrective therapy to improve vascularization in the tumor by inhibiting vascular endothelial growth factor A (VEGF-A) signaling has been clinically beneficial in glioblastoma, lung cancer and age-related macular degeneration ([@B4]). The most widely used anti-VEGF-A monoclonal antibody, bevacizumab, was also shown to rectify aberrant neovascularization and improve small-molecule uptake in TB granulomas in rabbits ([@B35]). Pharmacological inhibition of angiogenesis with pazopanib (tyrosine kinase inhibitor approved for renal cell cancer) in the zebrafish model of *Mycobacterium marinum* infection -- which can recapitulate the early inflammatory events in human pulmonary TB -- also enabled improved vascularization and enhanced anti-TB drug penetration into lesions, coupled with reduced bacterial dissemination to other parts of the host ([@B159]). With relevance to immune-cell metabolism, VEGF-A neutralization using bevacizumab in mice fed with a high-fat diet reversed insulin resistance in the liver and adipose tissue, decreasing blood sugar levels ([@B260]). However, while VEGF-A inhibition improves anti-cancer drug access to the tumor tissue, it has also been shown to reduce tissue oxygenation and induce acute hypoxia in diseased tissue in patients with cancer ([@B16]; [@B233]), unlike the observation within bevacizumab-treated pulmonary TB lesions in rabbits ([@B35]). VEGF-A utility in chronic infectious disease requires validation in well-designed early phase clinical studies using suitable patient cohorts.

Immunomodulation by Cholesterol-Lowering Drugs
----------------------------------------------

Statin intake among patients with severe influenza has shown a link with decreased inflammation and MHC class II downregulation in addition to reduction in serum lipids and lower incidence of death ([@B237]). The use of atorvastatin among patients with HIV infection may result in less activated and less exhausted T-cell populations (downregulation of HLA-DR, TIM-3, and PD-1) while pravastatin contributes to higher numbers of circulating antigen-specific IFN-γ+ CD8+ T cells ([@B163]). The cellular target of statins is β-hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase ([@B115]). A hallmark of statin-based HMG-CoA reductase inhibition is the abrogation of the mevalonate pathway which leads to production of isoprenyl pyrophosphate (IPP) -- an intermediary that is indispensable for cholesterol synthesis ([@B24]). While both atorvastatin (Lipitor^®^) and pravastatin (Pravachol^®^, Selektine^®^) block HMG-CoA reductase aptly, the former does so in a reversible fashion ([@B90]). It also important to mentioned here that, while atorvastatin is more potent than pravastatin at lowering blood cholesterol levels, it also impairs mitochondrial function ([@B234]).

In addition to cholesterol synthesis, IPP is also a direct agonist of Vγ9Vδ2 T-cell activation ([@B253]). Vγ9Vδ2 T cells represents a particular TCR-γδ population that is prevalent in blood and has been shown to be associated with anti-viral ([@B2]; [@B179]), anti-bacterial ([@B221]; [@B189]; [@B178]) and anti-tumor ([@B152]; [@B111]; [@B156]) activity. Reduced cholesterol production -- due to halted IPP turnover -- triggers an upregulation of the low-density lipoprotein (LDL) receptor on cells, leading to an accumulation of intracellular LDL and a dramatic decrease in circulating levels of 'bad' cholesterol ([@B1]). This phenomenon (high LDLR expression in addition to high intracellular LDL content) in Vγ9Vδ2 T cells has been shown to compromise their immune functions in association with reduced mitochondrial ATP generation and dampened pro-inflammatory functions against breast cancer cells ([@B190]). Given the growing importance of Vγ9Vδ2 T cells in the host's armament against infectious agents, i.e., *M.tb*, pathogenic *Escherichia coli*, CMV, *Plasmodium falciparum* etc. ([@B39]; [@B262]; [@B248],[@B249]; [@B26]; [@B97]; [@B196]), there is a high likelihood that the use of statins may not promote immune activation but rather immune suppression in patients -- most likely dependent on the disease state. Further to Vγ9Vδ2 T cells, inhibition of HMG-CoA also leads to impaired B-cell activation and their subsequent capacity to activate CD4+ T cells via HLA-DR upregulation and antigen presentation ([@B209]). Therefore, statin adjunctive therapy may be considered for inducing anti-inflammatory effect to ameliorate chronic infection rather than to stimulate immune responses for improving clinical outcomes.

Another cholesterol-lowering drug, ezetimibe, has also shown potency against intracellular *M.tb* under hypoxic conditions ([@B232]). Furthermore, the study also reported that patients receiving ezetimibe therapy exhibited a lower incidence of LTBI as well as intracellular lipid content, concomitant with reduced bacterial reservoirs ([@B232]). However, like statins but via a different mechanism, ezetimibe also has anti-inflammatory properties which downregulates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) expression and monocyte chemotactic protein 1 (MCP-1) production albeit with a chance of increasing NO expression ([@B230]). NO is a strong mediator of intracellular antimicrobial responses in APCs, i.e., macrophages and dendritic cells, and in modulating T-cell responses ([@B157]; [@B231]). Further to an immunological component, NO is a major intracellular communication molecule involved in vascular integrity and neuronal function ([@B15]). Low NO levels was shown to be associated with dyslipidaemia in patients with T2DM, suggesting a role for NO in modulating lipid metabolism ([@B144]).

Non-steroidal Anti-inflammatory Drugs
-------------------------------------

The role of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen has been previously explored as adjunctive therapy for tissue protection in severe lung infections, including TB ([@B50]; [@B242]; [@B113]) and influenza ([@B52]). Although these drugs target cyclooxygenases (COX), crucial enzymes in the eicosanoid pathway for production of lipid mediators such as prostaglandins and leukotrienes, exposure to aspirin in particular has been observed to induce NO synthesis in several cell types ([@B223]; [@B197]). Also, aspirin has been shown to induce the expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase -- which leads to ROS generation -- in adipocytes ([@B239]), that can also harbor *M.tb* bacilli ([@B11]). Thus, aspirin-induced NO and ROS production may shift the balance to reflect increased intracellular ROS concentrations without necessarily prompting exaggerated pro-inflammatory cytokine release ([@B148]; [@B93]).

Sirtuin Activation as an HDT Strategy
-------------------------------------

Sirtuin 1 (SIRT1) is an enzyme which participates in epigenetic modification of the genome and possesses mono-ADP-ribosyltransferase activity ([@B109]). The histone deacetylation properties of SIRT1 is involved in regulating the expression of genes involved in lipid and glucose metabolism as well as mitochondrial biogenesis in cells ([@B109]). In patients with T2DM, SIRT1 expression is downregulated, concomitant with insulin resistance and impaired FAO ([@B109]). Individuals suffering from obesity showed improvement in lipid metabolism, marked by increased SIRT1 expression, improved mitochondrial turnover and function as well as reduced amounts of intracellular lipid storage and circulating glucose levels ([@B229]). Resveratrol-mediated SIRT1 activation has been shown to interrupt the pro-inflammatory activity of CD4+ T cells ([@B268]), while myeloid cell-specific inactivation of the SIRT1 gene in a murine model of pulmonary TB resulted in amelioration of lung pathology, resolution of chronic inflammation and improved responses to anti-TB drug treatment ([@B27]). The therapeutic potential of SIRT1 activation in lung infections -- by means of metabolic reprogramming -- may suggest more favorable clinical outcomes and warrants the design of appropriate early-phase clinical trials.

HDT Candidates Currently in Clinical Trials
-------------------------------------------

Cyclic adenosine-monophosphate guanosine monophosphate (cGAMP) is a naturally occurring cyclic dinucleotide structure produced by cyclic GMP-AMP synthase (cGAS) in response to DNA stimulation ([@B217]). cGAMP also happens to be the natural agonist of the innate immune response-activating molecule stimulator of interferon genes (STING) -- which is important for inducing type 1 interferon production ([@B217]). Administration of exogenous cGAMP followed by STING stimulation was recently shown to result in rectification of glucose and lipid metabolism in mice fed with a high-fat diet by reducing lipid deposition in the liver as well as gluconeogenesis ([@B84]). Furthermore, cGAMP treatment lead to a decrease in pro-inflammatory responses in hepatocytes and adipocytes concomitant with an increase thereof in myelocytic cells ([@B84]). A novel STING agonist, ADU-S100, is currently in clinical trials sponsored by Novartis and Aduro Biotech to stimulate anti-cancer immune responses in patients with solid tumors ([ClinicalTrials.gov](https://ClinicalTrials.gov) identifiers: NCT02675439, NCT03172936). Preclinical assessment of ADU-S100 showed that, in combination with anti-PD-1 therapy, the drug promotes CD8+ T-cell infiltration into tumors while, on its own, type I interferon and TNF-α induction in haematopoietic cells was observed ([@B44]). While immune-stimulation is not necessary for patients with active infection-induced lung pathology, the use of ADU-S100 may be considered to engage innate immune mechanisms as well as tissue-associated T-cell responses ([@B160]) for eradicating 'silent' pathogen reservoirs in individuals harboring asymptomatic/latent infections, i.e., LTBI, *Cryptococcus neoformans* infection in HIV-infected adults ([@B143]), respiratory viral infections in young children ([@B28]) and drug-resistant *Klebsiella pneumoniae* as well as *Acinetobacter baumannii* infections ([@B251]; [@B180]). Considering that cGAMP and STING activation also influences the normalization of metabolic dysregulation in the host, individuals with dyslipidaemia or DM and latent lung infections may also benefit from cGAMP/STING-targeted therapy for enhancing immune responses while correcting their metabolic profile.

Another clinical drug candidate targeting host metabolism is dactolisib (BEZ235), which is currently in early-phase clinical trials for patients with solid cancers ([@B151]). Dactolisib is an inhibitor of the PI3K/mTOR pathway and was tested in influenza-infected human cells, resulting in strong impairment of glycolysis and a stark reduction in viral titres albeit not affecting virus entry, genome replication and gene transcription in cells ([@B212]). *In vivo* evaluation of the drug (in mice infected with influenza A virus) showed that the drug was well tolerated and a reduction in pathogen burden as well as extension of survival was achieved ([@B212]). This places dactolisib on the list of candidates for host-directed adjunct therapies further to conventional antimicrobials, warranting further evaluation in clinically relevant models representing suitable indications.

[Table 1](#T1){ref-type="table"} is a summary of clinically approved drugs or candidates with HDT properties that can modulate host immune metabolism to improve disease outcomes, which are presently in clinical trials. [Figure 1](#F1){ref-type="fig"} summarizes the dysregulation of host immunometabolism in pulmonary infections and presents several of the afore-mentioned therapeutic agents that may be considered in a host-directed fashion to restore a dysregulated immunometabolism or to fine-tune the metabolic milieu to the effect of decreasing detrimental immunopathology while enhancing specific and protective immune responses.

###### 

Drugs (clinically approved and candidates in clinical trials) capable of altering host immunometabolism to improve clinical outcomes in pulmonary infections.

  Drug/chemical compound                                                           Biological target                       Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               References
  -------------------------------------------------------------------------------- --------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  **Clinically approved agents**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Metformin                                                                        Activation of AMPK                      Clinically approved to treat T2DM. Increases mitochondrial respiration and FA breakdown, leading to increased generation of memory CD8+ T cells. Shown to enhance immune clearance of *M.tb* in murine models.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            [@B211]
  Bevacizumab                                                                      VEGF                                    Used in the treatment of glioblastoma. Corrects aberrant neovascularization in cancer tissue, allowing for oxygenation and reduction of hypoxia. Has been shown to improve vascular remodeling in TB granulomas, also increasing drug penetration. This is bound to affect immune-cell infiltration and anti-pathogen activity *in situ* due to an increase in oxygen, which enables aerobic glycolysis.                                                                                                                                                                                                                                                                                                                                                                                                                                  [@B35]; [@B159]
  Ipilimumab                                                                       CTLA-4                                  Both anti-CTLA-4 and anti-PD-1 are clinically approved for treating metastatic melanoma while the latter is also approved for treatment-refractory non-small cell lung cancer. Shown in the cancer setting to cause a shift to FAO from glucose metabolism, reminiscent of memory CD8+ T cells, including reduced uptake of glucose from the extracellular environment, thereby modulating the ability of T cells to acquire effector functions and produce IFN-γ. CTLA-4, on the other hand, inhibits glycolysis without switching the cell metabolism to FAO. This might have implications in patients with diabetes and lung infections, where high blood glucose level is a characteristic; PD-1-expressing antigen-specific T cells may be long-lived (like central memory cells) and highly amenable to therapeutic intervention.   [@B168]
  Nivolumab, pembrolizumab                                                         PD-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Statins, i.e., atorvastatin, pravastatin, lovastatin, simvastatin                HMG-CoA reductase                       Blocks the enzymatic activity of HMG-CoA reductase which catalyzes an important intermediate step in the isoprenoid pathway: conversion of HMG-CoA to mevalonate. Downstream of this process is the synthesis of isoprenyl pyrophosphate, which is necessary for cholesterol synthesis as well as Vγ9Vδ2 T-cell activation. Statin use in the cancer setting has shown to reduce Vγ9Vδ2 T cell-mediated tumor rejection owing to increased LDLR expression, increased LDL uptake and compromised mitochondrial function. However, statins could be useful against chronic inflammatory processes during infectious disease pathogenesis, i.e., TB.                                                                                                                                                                                        [@B253]; [@B234]; [@B190]
  Ezetimibe                                                                        Nieman-Pick-C1-Like1 (NPC1L1) protein   Ezetimibe blocks the reabsorption of cholesterol by cells, thereby reducing the amount of intracellular LDL levels. Has anti-inflammatory properties but may induce NO expression. It has been shown to reduce intracellular *M.tb* survival in macrophages while patients with T2DM taking ezetimibe have lower incidence of LTBI.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       [@B230]; [@B232]
  Aspirin (potentially also other non-steroidal anti-inflammatory drugs, NSAIDs)   Activation of NO/ROS release            NO is an important biological mediator as well as immune effector molecule, particularly against intracellular pathogens -- as is the ROS hydrogen peroxide (H~2~O~2~). Maybe involved in lipid metabolism, based on observations in patients with T2DM. Aspirin-driven NO production in macrophages and dendritic cells (as well as adipocytes) may, in fact, promote eradication of local bacterial reservoirs in the case of TB without raising an exaggerated immune response.                                                                                                                                                                                                                                                                                                                                                        [@B223]; [@B15]; [@B157]; [@B231]; [@B148]; [@B197]; [@B50]; [@B239]; [@B242]; [@B52]; [@B11]; [@B113]; [@B144]
  Resveratrol (also metformin)                                                     Activation of SIRT1                     Sirtiun 1 (SIRT1) is an important histone deacetylase with functions in modulating lipid metabolism as well as immune regulation in myelocytic and lymphocytic cells. Treatment of obese individuals with resveratrol improved lipid metabolism and reduced circulating levels of fatty acids and glucose as well as inflammatory markers. Resveratrol-mediated SIRT1 activation results in dampened pro-inflammatory CD4+ T cells responses as well as resolution of chronic lung inflammation and associated tissue pathology in mice infected with *M.tb*.                                                                                                                                                                                                                                                                             [@B229]; [@B268]
  Candidates in clinical trials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ADU-S100                                                                         Activation of STING pathway             ADU-S100 is a synthetic cyclic dinucleotide mimicking the structure of cGAMP and is currently in clinical trials as an agonist of the STING pathway. Recent evidence demonstrates that STING activation via cGAMP allows for correction of lipid/glucose metabolism dysregulation while enhancing innate and adaptive immune responses, i.e., type I interferon production and CD8+ T-cell activity. This has implications for eradicating latent pathogen reservoirs, i.e., LTBI, *Cryptococcus* sp. infections, asymptomatic *Klebsiella* spp. infection in individuals, including those who suffer from metabolic conditions/diseases.                                                                                                                                                                                                 ([@B143]; [@B251]; [@B180]; [@B28]; [@B160]; [@B44]); [ClinicalTrials.gov](http://ClinicalTrials.gov) identifiers: NCT02675439, NCT03172936
  Dactolisib (BEZ235)                                                              PI3K/mTOR pathway                       Dactolisib inhibits the PI3K/mTOR pathway to the effect of abrogating glycolysis in exposed cells. This has shown benefit in ameliorating deleterious lung pathology in influenza A infection while extending survival (murine model). Dactolisib is currently in clinical trials for patients with cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               [@B212]; [@B151]

AMPK, adenosine monophosphate-activated protein kinase; T2DM, type II diabetes mellitus; VEGF, vascular endothelial growth factor; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; PD-1, programmed cell death 1; FAO, fatty acid oxidation; LDL, low-density lipoprotein; NO, nitric oxide; ROS, reactive oxygen species; NSAID, non-steroidal anti-inflammatory drug; cGAMP, cyclic guanosine-monophosphate adenosine-monophosphate; STING, stimulator of interferon genes; LTBI, latent tuberculosis infection; PI3K, phosphatidylinositol-3-kinase; mTOR, mammalian target of rapamycin

.

![Targeting the host immunometabolism to treat lung infections. A schematic representation of the central role played by glucose and lipid metabolism in immune-cell homeostasis and control of pulmonary infection(s). Uptake of free fatty acids as well as glucose by T and B cells is important for immunological effector functions and maintenance of immune-cell memory. In this regard, saturated fatty acids may have a higher likelihood of promoting anti-inflammatory activity in T cells, while unsaturated fatty acids may lead to the contrary. Antigen-presenting cells (APCs), encompassing macrophages, dendritic cells and B cells, are affected by the intake and endogenous production of fatty acids in their capacity to generate phagolysosomes and upregulate HLA-DR on the cell surface to activate T cells. Similarly, glucose metabolism in B cells is important for cellular proliferation and antibody production. However, infected myeloid cells, represented here by an *M.tb*-infected macrophage (Mf), can disrupt the fatty acid-metabolic balance by increasing consumption of both nutrient types as indicated by the thicker arrows. This loss of equilibrium results in bacterial proliferation, subdued immune activation/modulation and survival of the pathogen in the lung. Furthermore, high levels of circulating low-density lipoprotein (LDL) are also taken up by infected host cells to support intracellular survival of the pathogen. Interspersed in this intricate immuno-metabolic circuit are NK cells, which can also acquire adaptive, memory-like functions and contribute to effective host immune control of pulmonary pathogens. Glucose uptake is also necessary for effector NK cells with regard to IFN-γ production, which is essential for protection against intracellular pathogens. This is concomitant with mTOR upregulation and responsiveness to IL-2. However, the regulation of lipid immunometabolism in NK cells requires further investigation. Also shown in the figure are several drugs (in yellow/orange boxes), most of which are clinically approved except for ADU-S100 and dactolisib, which may be used for targeting the immunometabolic axis in lung infections. Metformin, via the activation of AMPK, can induce oxidative phosphorylation (OXPHOS) in macrophages and improve memory CD8+ T-cell responses (IFN-γ production). Statins block intracellular HMG-CoA reductase and induce an increase in LDL accumulation in exposed cells by upregulating surface expression of the LDL receptor, which can affect both T and B cells by reducing inflammatory responses. Conversely, ezetimibe, which also regulates cholesterol homeostasis, does so by blocking uptake of exogenous LDL. Ezetimibe, like statins, shows a rather anti-inflammatory effect and can induce nitric oxide (NO) production. Aspirin (acetylsalicylic acid), which was already proposed as a possible anti-inflammatory HDT for TB, may also induce NO expression in cells -- which is crucial for killing intracellular pathogens. Resveratrol can improve the uptake of free fatty acids by T cells by activating host sirtuin1 (SIRT1) -- to fine-tune cellular immune responses while reducing the occurrence of adverse tissue pathology. Although not directly shown, anti-PD-1 and anti-CTLA-4 therapy have been shown to improve glucose metabolism in T-cell populations, in part adding to their clinical anti-tumor activity and may also apply to TB. The investigational clinical drug candidate ADU-S100 mimics cyclic guanosine-monophosphate-adenosine-monophosphate (cGAMP) and can activate the stimulator of interferon genes (STING) protein, thus qualifying it as an immunomodulatory drug candidate with effects on immunometabolism. Dactolisib is currently in early-phase clinical trials to treat patients with solid cancers and has been shown to be beneficial in a preclinical murine influenza infection model -- by targeting glycolysis and may apply to TB and staphylococcal infections, where increased glycolysis in host cells supports pathogen growth.](fmicb-10-00962-g001){#F1}

Conclusion
==========

The role of cellular metabolism in immunomodulation is an integral component of HDTs. Existing evidence, based on preclinical and clinical observations, suggest that metabolism-targeting drugs given in an adjunct fashion to standard antimicrobial therapy may lead to clinical benefits. In addition, immunometabolic modulatory axes -- marked by transcriptional regulation and post-transcriptional as well as epigenetic checkpoints -- need to be considered in the process of designing HDTs. An integrated view of information supplied by ongoing clinical trials ('drug repurposing') in various patient populations -- including dietary practices, genetic backgrounds and exposure to pathogens -- is critical in our collective attempts to improve clinical outcomes in treating pulmonary infections.
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We searched Google, PubMed, and NCBI using the terms 'immunometabolism,' 'immune-metabolism,' 'metabolism of immune cells,' 'metabolic programming of immune cells,' and 'immunometabolic programming' in the context of and linking pulmonary infections, tuberculosis, diabetes and metabolic diseases. We also used these terms to obtain information concerning relevant drugs and host-directed therapies. All searches for the first submission and revision were performed between June 2018 and March 2019. Irrelevant search results not covered in the scope of this review were eliminated prior to use in discussion for the text.
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